HC Wainwright Forecasts Surrozen FY2026 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Equities researchers at HC Wainwright issued their FY2026 earnings per share estimates for Surrozen in a report released on Tuesday, November 10th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($12.01) per share for the year. HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2026 earnings at ($1.40) EPS, FY2027 earnings at ($5.19) EPS, FY2028 earnings at ($5.46) EPS, FY2029 earnings at ($5.64) EPS and FY2030 earnings at ($5.35) EPS.

Several other research firms have also weighed in on SRZN. Zacks Research raised Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, October 15th. Guggenheim set a $80.00 target price on Surrozen and gave the company a “buy” rating in a research note on Wednesday. William Blair initiated coverage on Surrozen in a report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 target price on the stock. Finally, Cantor Fitzgerald increased their price target on shares of Surrozen from $40.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.75.

Surrozen Stock Performance

NASDAQ SRZN opened at $31.88 on Thursday. Surrozen has a 1 year low of $12.12 and a 1 year high of $37.83. The business’s fifty day moving average is $25.54 and its two-hundred day moving average is $25.42. The stock has a market capitalization of $370.13 million, a P/E ratio of -0.74 and a beta of 0.51.

Surrozen (NASDAQ:SRZN) last released its earnings results on Monday, November 9th. The company reported ($11.02) EPS for the quarter, missing the consensus estimate of ($1.10) by ($9.92).

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SRZN. Perceptive Advisors LLC acquired a new position in shares of Surrozen during the 1st quarter valued at about $6,682,000. Renaissance Technologies LLC lifted its holdings in Surrozen by 117.1% in the 1st quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock worth $1,431,000 after purchasing an additional 26,500 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Surrozen in the 2nd quarter worth approximately $399,000. ADAR1 Capital Management LLC bought a new stake in Surrozen during the first quarter worth approximately $350,000. Finally, Global Retirement Partners LLC bought a new stake in Surrozen during the third quarter worth approximately $45,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation. The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.